What Nabla Bio does
Nabla Bio is a Cambridge, Massachusetts-based AI-for-science company building generative protein-design technology for therapeutic discovery. The company’s stated objective is to make drug discovery “designable” by combining multimodal generative modeling with human-relevant experimental measurement rather than relying on purely iterative discovery cycles. Nabla’s platform centers on JAM (Joint Atomic Model), a generative modeling system that is trained on protein sequence/structure data and is strengthened with measurements generated by Nabla’s integrated wet-lab systems. Nabla positions JAM as a system that can take partial molecular context (such as a disease target or an epitope) and “autocomplete” the rest to enable de novo design (including epitope-precise antibody design), developability-aware optimization, and generative proposals for multispecific architectures.
In terms of target focus, Nabla highlights difficult protein classes—especially multipass membrane proteins such as GPCRs, ion channels, and transporters—where conventional discovery approaches face challenges due to limited extracellular accessibility, conformational dynamics, and selectivity against close off-targets. Operationally, Nabla’s approach is described as running design and measurement as one integrated engine: the company states it produces thousands of designs in mammalian systems and measures binding, developability properties, and cellular/in vivo function, with the intent of reducing “trial-and-error” and minimizing the need for iterative lab-in-the-loop screening.
Business model: Nabla states it works primarily through (1) partnerships with pharmaceutical companies to embed its AI-and-wet-lab platform across discovery pipelines and (2) licensing molecules it designs against disease targets. In its public materials, Nabla also describes delivering designed therapeutic candidates (e.g., antibodies and other protein therapeutics) generated from JAM and validated through its own functional assays.
Current strategic position (as reflected in recent public communications): Nabla’s most visible external traction in 2024–2025 includes a $11M seed round (2021) and a $26M Series A (May 14, 2024), plus ongoing and expanding multi-year research collaborations with Takeda. In October 2025, Nabla announced a second Takeda collaboration that includes upfront and research cost payments in double-digit millions and eligibility for success-based payments that may exceed $1B in total, with JAM deployed across Takeda’s early-stage development programs. In 2025 scientific communications, Nabla also published technical evidence emphasizing “test-time scaling” improvements to JAM for de novo antibody design against GPCR targets, including reported affinity and functional outcomes from wet-lab validation of computational designs.